Recent Updates
Recently added Catalysts

TYP03A Low Dose with Alum investigational vaccine

Phase 1

Typhoid Fever | Monoclonal antibody | Infectious Disease |GSK plc|Last Updated: Jan 24, 2025

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindACTIVE_CONTROLLED
Total Trials1
Total Enrollment97

FDA Designations

No designations recorded

Clinical trial landscape

TYP03A Low Dose with Alum investigational vaccine · 1 trial · 1 indication

Phase 1 1
NCT05613205Safety and Immunogenicity of a Novel Conjugate Vaccine Against Salmonella Typhi and Salmonella Paratyphi A in Healthy AdultsTyphoid Fever
COMPLETED97 Analytics
PHASE1COMPLETED
Safety and Immunogenicity of a Novel Conjugate Vaccine Against Salmonella Typhi and Salmonella Paratyphi A in Healthy Adults
Typhoid FeverUnlock trial analytics

Study Endpoints

Primary Endpoints

Number of Participants With Solicited Administration-site Events After the First Vaccination
From Day 1 to Day 7

Solicited administration site events included pain, redness, and swelling.

Number of Participants With Solicited Administration-site Events After the Second Vaccination
From Day 169 to Day 175

Solicited administration site events included pain, redness, and swelling.

Number of Participants With Solicited Systemic Events After the First Vaccination
From Day 1 to Day 7

The solicited systemic events included arthralgia (joint pain), fatigue (tiredness), fever, headache, and myalgia (muscle pain). Fever is defined as body temperature more than or equal to (\>=) 38.0 degrees Celsius (°C).

Number of Participants With Solicited Systemic Events After the Second Vaccination
From Day 169 to Day 175

The solicited systemic events included arthralgia (joint pain), fatigue (tiredness), fever, headache, and myalgia (muscle pain).

Number of Participants With Unsolicited Adverse Events (AEs) After the First Vaccination
From Day 1 to Day 28

An unsolicited AE is defined as an AE that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events.

Number of Participants With Unsolicited Adverse Events After the Second Vaccination
From Day 169 to Day 196

An unsolicited adverse event is defined as an adverse event that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events.

Number of Participants With Any Serious Adverse Events (SAEs)
From Day 1 to Day 197

An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, results in abnormal pregnancy outcomes or any other situation based on appropriate medical or scientific judgement.

Number of Participants With AEs/SAEs Leading to Withdrawal From the Study
From Day 1 to Day 197

Any AEs including SAEs that lead to withdrawal from the study are considered under this outcome measure. A participant is considered to have withdrawn from the study if no new study procedure has been performed or no new information has been collected for him/her since the date of withdrawal/last contact.

Number of Participants With SAEs Leading to Withholding Further Study Intervention Administration
From Day 1 to Day 197

An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, results in abnormal pregnancy outcomes or any other situation based on appropriate medical or scientific judgement. SAEs that lead to withholding of the study intervention administration were considered under this outcome measure.

Number of Participants With AEs Leading to Withholding Further Study Intervention Administration
From Day 1 to Day 197

An AE is any untoward medical occurrence (an unfavourable/unintended sign - including an abnormal laboratory finding), symptom, or disease (new or exacerbated) in a clinical study participant that is temporally associated with the study intervention. AEs that lead to withholding of the study intervention administration were considered under this outcome measure.

Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 8
At Day 8 compared to Day 1 (Baseline)

Assessed hematological laboratory parameters include basophils, eosinophils, erythrocytes, hemoglobin, hematocrit, lymphocytes, monocytes, neutrophils, platelets, leukocytes. Hepatic laboratory parameters include alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\] and renal laboratory parameters include creatinine and blood urea. Categories reported when comparing Day 1 (baseline) and Day 8 hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>-\<range at baseline\>-\<range at timing\> (e.g. ALT-Within-Within). Range level being classified as below, within or above the normal range.

Number of Participants With Deviations From Normal or Baseline Values of Haematological, Renal, and Hepatic Panel Test Results at Day 176
At Day 176 compared to Day 169 (Baseline)

Assessed hematological laboratory parameters include basophils, eosinophils, erythrocytes, hemoglobin, hematocrit, lymphocytes, monocytes, neutrophils, platelets, leukocytes. Hepatic laboratory parameters include alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\] and renal laboratory parameters include creatinine and blood urea. Categories reported when comparing Day 169 (baseline) and Day 176 hematological, renal and hepatic laboratory results are defined as follows: \<parameter\>-\<range at baseline\>-\<range at timing\> (e.g. ALT-Within-Within). Range level being classified as below, within or above the normal range.

Secondary Endpoints

Number of Participants With Any SAE
From Day 197 to Day 337
Number of Participants With AEs/SAEs Leading to Withdrawal From the Study
From Day 197 to Day 337
Geometric Mean Concentrations (GMCs) of Anti-Vi Antigen Immunoglobulin G (IgG) Antibody Concentrations
At Day 1 (pre-dose 1), Day 29, Day 169 (pre-Dose 2), Day 176 and Day 197
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelSEQUENTIAL
PurposePREVENTION

Treatment Arms

ArmTypeDescription
Step 1a: Low dose TYP04A vaccine without AlumEXPERIMENTALParticipants received low dose of the TYP04A vaccine without Alum intramuscularly on Day 1 and Day 169.
Step 1b: Low dose TYP03A vaccine with AlumEXPERIMENTALParticipants received low dose of the TYP03A vaccine with Alum intramuscularly on Day 1 and Day 169.
Step 2: Full dose TYP04B vaccine without AlumEXPERIMENTALParticipants received full dose of the TYP04B vaccine without Alum intramuscularly on Day 1 and day 169.
Step 2: Full dose TYP03B vaccine with AlumEXPERIMENTALParticipants received full dose of the TYP03B vaccine with Alum intramuscularly on Day 1 and day 169.
Control: TYPHIM VI and BOOSTRIX vaccineACTIVE_COMPARATORParticipants received TYPHIM VI as comparator intramuscularly on Day 1, and BOOSTRIX as comparator on Day 169.

Interventions

NameTypeDescription
TYP04A Low Dose without Alum investigational vaccineBIOLOGICAL2 doses of TYP04A Low Dose without Alum investigational vaccine administered intramuscularly as a priming dose on Day 1 and a booster dose on Day 169.
TYP04B Full Dose without Alum investigational vaccineBIOLOGICAL2 doses of TYP04B Full Dose without Alum investigational vaccine administered intramuscularly as a priming dose on Day 1 and a booster dose on Day 169.
TYP03A Low Dose with Alum investigational vaccineBIOLOGICAL2 doses of TYP03A Low Dose with Alum investigational vaccine administered intramuscularly as a priming dose on Day 1 and a booster dose on Day 169.
TYP03B Full Dose with Alum investigational vaccineBIOLOGICAL2 doses of TYP03B Full Dose with Alum investigational vaccine administered intramuscularly as a priming dose on Day 1 and a booster dose on Day 169.
Sanofi Pasteur's Typhoid Vi polysaccharide vaccineBIOLOGICAL1 dose of Sanofi Pasteur's Typhoid Vi polysaccharide vaccine administered intramuscularly, at Day 1, to participants in the control group.
GSK's Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccineBIOLOGICAL1 dose of GSK's Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine administered intramuscularly, at Day 169, to participants in the control group.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 50 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Participants who, in the opinion of the Investigator, can and will comply with the requirements of the Protocol (e.g., completion of the diary cards, return for follow-up visits). * Written informed consent obtained from the participant prior to performance of any study specif...

Countries:Belgium
Unlock Eligibility Criteria

Frequently asked questions about TYP03A Low Dose with Alum investigational vaccine

What is TYP03A Low Dose with Alum investigational vaccine used for?

TYP03A Low Dose with Alum is an investigational vaccine being developed for the prevention of typhoid fever, a serious infectious disease caused by Salmonella Typhi. It is currently in Phase 1 clinical development and has not been approved for use.

Who makes TYP03A Low Dose with Alum investigational vaccine?

TYP03A Low Dose with Alum is being developed by GSK plc, a global biopharma company listed on the stock exchange under the ticker GSK. The vaccine is currently in Phase 1 clinical trials for typhoid fever.

What phase is TYP03A Low Dose with Alum investigational vaccine in?

TYP03A Low Dose with Alum is in Phase 1 clinical development. It is an investigational vaccine and has not been approved by regulatory authorities. One Phase 1 trial has been completed, and the vaccine is not yet available for public use.

What clinical trials is TYP03A Low Dose with Alum investigational vaccine in?

TYP03A Low Dose with Alum has been studied in one completed Phase 1 clinical trial, identified as NCT05613205. This trial evaluated the safety and immunogenicity of a novel conjugate vaccine against Salmonella Typhi and Salmonella Paratyphi A in healthy adults in Belgium.

Is TYP03A Low Dose with Alum investigational vaccine the same as a conjugate vaccine?

TYP03A Low Dose with Alum is an investigational vaccine being studied for typhoid fever. The completed clinical trial NCT05613205 evaluated a novel conjugate vaccine against Salmonella Typhi and Salmonella Paratyphi A, which is the formulation being tested in this development program.